Register today for ACS Clinical Congress 2024, October 19–22 in San Francisco, California. Both in-person and virtual attendance options are available.
While at Clinical Congress, plan to attend these Cancer Programs sessions on Tuesday, October 22. Click on the title link to add the session to your interactive program planner.
PS303. Ductal Carcinomas in Situ (DCIS): Where Are We in 2024? Who Needs an Operation and Who Doesn’t?
8:00–9:30 am PT
301–302 Level 3 South
Moderator: Catherine E. Pesce, MD, FACS
Co-Moderator: Rachel A. Greenup, MD, FACS
Panelists will discuss the rapidly changing management of Ductal Carcinoma In Situ (DCIS). The latest retrospective literature now suggests that some cases of DCIS may be treated with observation or with de-escalation and soon the results of the Comparison of Operative to Monitoring and Endocrine Therapy for low-risk ductal carcinoma In Situ (COMET) trial will determine if observation of DCIS is safe in certain patients.
PS313. ACS Operative Standards in Cancer Surgery: Recommendations for Resection of Primary Adrenal, Neuroendocrine, and Thyroid Malignancies
9:45–11:15 am PT
306–308 Level 3 South
Moderator: Barbra S. Miller, MD, FACS
Co-Moderator: Tracy S. Wang, MD, FACS
In this cutting-edge session, authors from the American Association of Endocrine Surgeons and the Society of Surgical Oncology who led the recently published ACS Operative Standards in Cancer Surgery sections on adrenal cancer, neuroendocrine cancers of the gastrointestinal tract and pancreas, and thyroid cancer will review in detail the technical aspects of resection of these malignancies. The session will include a video demonstration and question and answer period.
ME301. National Accreditation Program for Rectal Cancer: Who, What, Why, and How?
11:30 am–12:30 pm PT
101 Lobby Level South
Join this Cancer Programs Meet the Experts session to learn more about the National Accreditation Program for Rectal Cancer (NAPRC), which was developed through a collaboration between the OSTRiCH (Optimizing the Surgical Treatment of Rectal Cancer) consortium and the Commission on Cancer (CoC). The NAPRC aims to standardize and improve care using a multidisciplinary approach.
PS317. Updates in the Multidisciplinary Evaluation and Management of Pancreatic Cystic Neoplasms
12:45–2:15 pm PT
301–302 Level 3 South
Moderator: Rebecca Snyder, MD, FACS
Co-Moderator: William Burns, MD, FACS
Panelists will review best practices for the diagnostic evaluation of pancreatic cysts, current evidence regarding the role of molecular analysis, surgical decision-making, and optimal surveillance strategies in asymptomatic, low-risk patients.
